Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database

The Therapeutic Applications of and Risks Associated With Acetaminophen Use

(2014) James Guggenheimer et al.   JOURNAL OF THE AMERICAN DENTAL ASSOCIATION

The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C

(2013) B. Maasoumy et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Review of drug interactions with telaprevir and antiretrovirals

(2013) Rolf PG van Heeswijk et al.   ANTIVIRAL THERAPY

Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.

(2013) Marc Bifano et al.   ANTIVIRAL THERAPY

Psychiatric treatment considerations with direct acting antivirals in hepatitis C

(2013) Sanjeev Sockalingam et al.   BMC GASTROENTEROLOGY

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study

(2013) Michael W. Fried et al.   HEPATOLOGY

Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but not an activator of PXR in vitro

(2013) Johanna Weiss et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

EASL Clinical Practice Guidelines: Management of hepatitis C virus infection

(2013)   JOURNAL OF HEPATOLOGY

A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice

(2013) R Douglas Bruce et al.   Expert Review of Clinical Pharmacology

Predicting drug–drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach

(2013) Karen Rowland Yeo et al.   Expert Review of Clinical Pharmacology

Direct-Acting Antiviral Agents for Hepatitis C Virus Infection

(2012) Jennifer J. Kiser et al.   Annual Review of Pharmacology and Toxicology

Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters

(2012) Annett Kunze et al.   BIOCHEMICAL PHARMACOLOGY

The high comorbidity burden of the hepatitis C virus infected population in the United States

(2012) Karly S Louie et al.   BMC INFECTIOUS DISEASES

The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers

(2012) Varun Garg et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetic Interactions Between the Hepatitis C Virus Protease Inhibitor Boceprevir and Ritonavir-Boosted HIV-1 Protease Inhibitors Atazanavir, Darunavir, and Lopinavir

(2012) Ellen G. J. Hulskotte et al.   CLINICAL INFECTIOUS DISEASES

Review and management of drug interactions with boceprevir and telaprevir

(2012) Jennifer J. Kiser et al.   HEPATOLOGY

Pharmacokinetic Interaction Between Boceprevir and Etravirine in HIV/HCV Seronegative Volunteers

(2012) Kyle P. Hammond et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Clinical management of drug–drug interactions in HCV therapy: Challenges and solutions

(2012) David Burger et al.   JOURNAL OF HEPATOLOGY

Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial

(2012) Maribel Rodriguez-Torres et al.   JOURNAL OF HEPATOLOGY

Opioid Metabolism

(2012) Howard S. Smith   MAYO CLINIC PROCEEDINGS

Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 Countries

(2011) H. Quan et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers

(2011) Alicia J. Allred et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Statin myopathy: A common dilemma not reflected in clinical trials

(2011) G. FERNANDEZ et al.   CLEVELAND CLINIC JOURNAL OF MEDICINE

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

(2011) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

(2011) Bruce R. Bacon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C

(2010) Peter Derek Christian Leutscher et al.   HEPATOLOGY

Insurance status and treatment candidacy of hepatitis C patients: Analysis of population-based data from the United States

(2010) Maria Stepanova et al.   HEPATOLOGY

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

(2010) Paul Y Kwo et al.   LANCET

Comorbidities associated with the increasing burden of hepatitis C infection

(2010) Benjamin Basseri et al.   LIVER INTERNATIONAL

HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality

(2009) Nikolai Mühlberger et al.   BMC PUBLIC HEALTH

Predicting the Clinical Relevance of Drug Interactions From Pre-Approval Studies

(2009) Silvio Caccia et al.   DRUG SAFETY

The Simcyp®Population-based ADME Simulator

(2009) Masoud Jamei et al.   Expert Opinion on Drug Metabolism & Toxicology

Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response

(2009) Matthijs L. Becker et al.   Pharmacogenetics and Genomics

Hepatitis C comorbidities affecting the course and response to therapy

(2009) Abdel-Rahman El-Zayadi   WORLD JOURNAL OF GASTROENTEROLOGY